Calyxt, Inc. — 2017 Form 10-K
Issuer note: The request identifies Cibus, Inc., but the supplied filing is for Calyxt, Inc. This is an annual report for the fiscal year ended December 31, 2017, not a standalone fourth-quarter filing. Amounts below are in U.S. dollars.
Business context and reporting period
Calyxt is an early-stage agricultural biotechnology company developing gene-edited crops and specialty food ingredients using TALEN technology. Its pipeline includes high-oleic soybeans, high-fiber and herbicide-tolerant wheat, and other traits. At year-end, the high-oleic soybean was in Phase III; the company expected commercialization by the end of 2018. Calyxt had not generated product-sales revenue.
Calyxt completed its IPO in July 2017, raising approximately $58.0 million net. Parent Cellectis owned approximately 79.7% of Calyxt at December 31, 2017 and retained substantial governance and approval rights.
Financial results and liquidity
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | $0.508 million | $0.399 million |
| Research and development expense | $11.556 million | $5.638 million |
| Selling, general and administrative expense | $14.741 million | $6.670 million |
| Operating loss | $25.789 million | $12.109 million |
| Net loss | $25.980 million | $12.086 million |
| Net loss per share | $1.12 | $0.62 |
| Net cash used in operating activities | $12.785 million | $9.237 million |
| Cash and cash equivalents at year-end | $56.664 million | $5.026 million |
- Revenue was mainly from research and development agreements; the company said it was reducing third-party R&D work to focus on its own pipeline. No product revenue had been recorded.
- Operating costs rose sharply as the company expanded product development and commercial preparation. Stock-based compensation was $11.720 million in 2017, including IPO-triggered vesting expense.
- Cash provided by financing was $65.202 million, principally from the IPO and approximately $7.0 million of proceeds from the Roseville property sale-leaseback. Investing activities used $0.779 million.
- Year-end current assets were $57.457 million and current liabilities $4.254 million. Total liabilities were $14.691 million, including a $10.148 million financing-lease obligation. Contractual lease payments totaled $30.042 million on an undiscounted basis; this is not equivalent to conventional funded debt.
- Management expected available cash to fund operations through at least mid-2019; Cellectis had guaranteed funding through August 2018. The company warned that estimates depend on assumptions and additional capital might be needed.
Margins are not meaningful indicators of commercial performance at this stage: revenue was limited to R&D arrangements, with no product sales, and the company reported substantial operating losses.
Material changes versus prior periods
- Revenue rose 27% from 2016, but remained below $1 million and was affected by recognition of deferred revenue after R&D agreements terminated early.
- R&D expense increased 105% and SG&A increased 121% year over year; the net loss more than doubled. Management attributed much of the expense growth to stock compensation, staffing, external development work, and public-company costs.
- Operating cash use increased to $12.785 million from $9.237 million. The IPO substantially increased year-end cash and equity.
- The Roseville headquarters transaction added a long-term financing-lease commitment. The new facility was expected to become operational around May 2018.
Outlook, risks, contingencies, and unusual items
- Outlook: Management targeted high-oleic soybean commercialization by the end of 2018, contingent on building seed, grain and oil supply, securing tolling arrangements, and customer testing. High-fiber wheat could launch in 2020–2021; timing and success were uncertain. Calyxt expected continued losses and rising R&D and commercialization spending.
- Commercial and regulatory risks: The company had no commercial track record and depended on farmer and food-company adoption, third-party supply-chain performance, successful field trials, scalable production, and evolving U.S. and international regulation. USDA had confirmed non-regulated status for six submitted product candidates, not the entire pipeline.
- Funding and control: The stated mid-2019 cash runway is forward-looking. Cellectis’s majority ownership and contractual rights could constrain corporate decisions; Calyxt also depended on Cellectis for services and licensed intellectual property.
- Intellectual-property litigation: After year-end, Calyxt alleged that Bayer breached a TALEN license agreement, gave termination notice, and filed suit in Delaware Chancery Court on March 12, 2018. Calyxt said it did not expect significant losses, but the outcome was uncertain and could affect competitive rights.
- Lease and inventory exposure: Calyxt is responsible for net-lease costs and construction cost overruns; Cellectis guaranteed the lease, subject to stated conditions, and Calyxt agreed to indemnify Cellectis if its ownership falls to 50% or less. Forward purchase commitments for seed and grain were approximately $1.6 million.
- Unusual accounting and tax items: IPO-related stock-option vesting contributed to significant noncash compensation expense. The 2017 loss included a $0.190 million foreign-currency transaction loss. Tax reform reduced the federal corporate rate, but deferred tax assets remained fully offset by a valuation allowance; the company reported $41.6 million in federal and state net operating losses.
- Controls: Management said disclosure controls were effective at year-end and reported remediation of a prior material weakness involving review of forward-purchase derivative contracts. The company did not provide a management assessment or auditor attestation of internal control over financial reporting in this filing, citing the transition period for newly public companies.
Important facts for investors to verify
- Whether the high-oleic soybean met its commercialization milestones, including supply-chain readiness, customer testing, crusher agreements, and actual sales.
- Cash burn, remaining runway, and financing needs relative to the mid-2019 estimate and Cellectis’s funding guarantee through August 2018.
- Actual costs and obligations under the Roseville financing lease, including construction overruns and ongoing net-lease expenses.
- The outcome and commercial intellectual-property consequences of the Bayer litigation and the status of Calyxt’s key licenses from Cellectis and other licensors.
- Progress and regulatory status of pipeline candidates, and whether field performance, production scale, customer demand, and farmer adoption support management’s market assumptions.
- The effects of Cellectis’s ownership, approval rights, related-party arrangements, and potential future share sales on governance and public shareholders.